Pelthos Therapeutics Inc. (PTHS) Stock

Pelthos Therapeutics Inc. (PTHS) is a Healthcare stock trading at $25.76 (as of 2026-08-21), with a market capitalization of $98.62M. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

Pelthos Therapeutics Inc., a bio-pharmaceutical company, develops and commercializes therapeutic products to help patients with unmet treatment burdens. The company offers ZELSUVMI for the treatment of molluscum contagiosum in adults and children 1 year of age and older. It also provides NITRICIL, a proprietary nitric oxide-based technology platform. The company was formerly known as Channel Therapeutics Corporation and changed its name to Pelthos Therapeutics Inc. in July 2025. Pelthos Therapeutics Inc. was founded in 2002 and is based in Durham, North Carolina.

Understand Pelthos Therapeutics Inc.: how it makes money

Pelthos Therapeutics develops and commercializes therapeutic products, including ZELSUVMI for molluscum contagiosum, and it also has a nitric oxide-based technology platform (NITRICIL) that can support licensing and collaboration revenue.

Because the company reports essentially no license and collaboration revenue in the latest quarter, its profit model is largely driven by ZELSUVMI net product sales, which in turn depend on prescription and dispensing activity.

Revenue by segment (latest quarter)
ZELSUVMI$0.0B

Business quality (Weak): ZELSUVMI appears to be the key revenue source, with strong gross margin but a deeply negative operating margin, suggesting high operating costs relative to current sales.

Bull case

  • High gross margin: Gross margin was 84.7% in the quarter ended 2026-03-31, indicating that reported product economics are favorable on a gross basis.
  • Real-world commercial activity exists: For ZELSUVMI, units prescribed and dispensed were 7,884, and unique prescribers were 3,228 in the same quarter, showing active commercialization.

Bear case

  • Operating losses remain large: Operating margin was -120.0% in the quarter ended 2026-03-31, indicating significant costs that overwhelm gross profit.
  • Revenue concentration in a single product, with limited diversification: License and collaboration revenue was 0.0 in the latest quarter, so reported revenue depends heavily on ZELSUVMI net product sales.
Valuation — source: SEC EDGAR (first-party)
Price$25.76
Market Cap$98.62M
Price / Sales2.91
FCF Yield-22.4%
Profitability & Growth — source: SEC EDGAR
Revenue (TTM)$16.80M
Net Margin-257.9%
Financial Health — source: SEC EDGAR
Altman Z-Score-0.57 (distress)
Valuation vs Sector & Industry
Sector P/E (Healthcare)21.7
Industry P/E (Pharmaceutical Products)17.2
Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional HolderMurchinson Ltd. ($6.23M)
Institutional Holders Tracked10
Company
SectorHealthcare
IndustryPharmaceutical Products
CEOScott Plesha
Employees4
CountryUS
IPO Date2025-07-02

Related Companies (Business model: Biotech (Clinical / Commercial-Stage); 8 closest by market cap; US-domiciled)

  • Black Diamond Therapeutics, Inc. (BDTX)
  • TScan Therapeutics, Inc. (TCRX)
  • ProKidney Corp. (PROK)
  • Kalaris Therapeutics Inc (KLRS)
  • Atara Biotherapeutics, Inc. (ATRA)
  • Cognition Therapeutics, Inc. (CGTX)
  • Outlook Therapeutics, Inc. (OTLK)
  • Cardiff Oncology, Inc. (CRDF)
PTHS earnings history · PTHS institutional & insider holders · PTHS KPIs & operating metrics · PTHS financials · PTHS investor presentations & press releases · PTHS SEC filings · PTHS peers · Congress trades · Insider trades · Short interest · Stock screener

Data as of 2026-08-21.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.